We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+13.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$25B
AUM Growth
+$2.35B
Cap. Flow
+$638M
Cap. Flow %
2.55%
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$358M
2
PRLD icon
Prelude Therapeutics
PRLD
+$286M
3
KYMR icon
Kymera Therapeutics
KYMR
+$59.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$55.5M
5
NRIX icon
Nurix Therapeutics
NRIX
+$45.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$94.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.6M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$21.6M
4
INSM icon
Insmed
INSM
+$21.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 97.35%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADPT icon
51
Adaptive Biotechnologies
ADPT
$3.51B
$21.4M 0.09%
440,539
-23,000
-5% -$967K
NVAX icon
52
Novavax
NVAX
$1.21B
$20.3M 0.08%
187,376
-54,000
-22% -$6.58M
IMMU
53
DELISTED
Immunomedics Inc
IMMU
$20.2M 0.08%
237,694
-92,306
-28% -$4.67M
ALBO
54
DELISTED
Albireo Pharma Inc
ALBO
$18.3M 0.07%
549,047
+180,000
+49% +$5.24M
KRRO icon
55
Korro Bio
KRRO
$146M
$18.2M 0.07%
18,991
+77
+0.4% +$82.7K
LONA
56
LeonaBio Inc
LONA
$66.4M
$16.3M 0.07%
+88,235
New +$14.7M
XNCR icon
57
Xencor
XNCR
$1.45B
$15.9M 0.06%
410,142
-17,978
-4% -$625K
BLUE
58
DELISTED
bluebird bio
BLUE
$13.6M 0.05%
19,454
-1,004
-5% -$783K
HRMY icon
59
Harmony Biosciences
HRMY
$2.06B
$13.6M 0.05%
+400,000
New +$14.6M
GWPH
60
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$13.5M 0.05%
138,745
-46,300
-25% -$5.33M
MIRM icon
61
Mirum Pharmaceuticals
MIRM
$6.59B
$10.7M 0.04%
553,009
-30,324
-5% -$651K
IMTX icon
62
Immatics
IMTX
$1.19B
$10.6M 0.04%
1,001,414
+851,414
+568% +$8.97M
VXRT
63
DELISTED
Vaxart
VXRT
$10.4M 0.04%
1,566,121
-73,000
-4% -$650K
ACGN
64
DELISTED
Aceragen Inc
ACGN
$9.86M 0.04%
271,376
– –
UROV
65
DELISTED
Urovant Sciences Ltd.
UROV
$9.14M 0.04%
978,505
-21,495
-2% -$191K
SGMO
66
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.98M 0.04%
949,823
-50,000
-5% -$541K
XENE icon
67
Xenon Pharmaceuticals
XENE
$6.16B
$8.42M 0.03%
760,308
-38,794
-5% -$456K
ISEE
68
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.93M 0.03%
1,406,037
-229,464
-14% -$1.09M
ANAB icon
69
AnaptysBio
ANAB
$1.53B
$7.19M 0.03%
487,243
-26,434
-5% -$477K
QURE icon
70
uniQure
QURE
$2.76B
$7.16M 0.03%
194,383
-36,500
-16% -$1.5M
CABA icon
71
Cabaletta Bio
CABA
$429M
$6.9M 0.03%
636,363
– –
HOOK
72
DELISTED
HOOKIPA Pharma
HOOK
$6.63M 0.03%
70,048
– –
SYRS
73
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.1M 0.02%
69,017
– –
KRTX
74
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$6.01M 0.02%
77,776
-4,200
-5% -$358K
BNR
75
Burning Rock Biotech
BNR
$94M
$5.95M 0.02%
23,730
-1,270
-5% -$301K
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, Baker Bros. Advisors held 126 positions worth $25B, up 10% from $22.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2020 filing shows 11 new, 17 increased, 63 reduced and 6 closed positions. Its largest new stake was Prelude Therapeutics: 10,118,636 shares worth $305M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2020 buy was Prelude Therapeutics: 10,118,636 shares worth $305M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q3 2020, an estimated $358M increase.
  • Baker Bros. Advisors's biggest Q3 2020 reduction was Neurocrine Biosciences, cutting an estimated $26.6M.
  • Baker Bros. Advisors fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $94.5M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $25B portfolio in Q3 2020.
  • Baker Bros. Advisors opened 11 new positions and closed 6 in Q3 2020.
  • Baker Bros. Advisors's portfolio value rose 10% quarter-over-quarter to $25B.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.